A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma Journal Article


Authors: Rusch, V.; Saltz, L.; Venkatraman, E.; Ginsberg, R.; McCormack, P.; Burt, M.; Markman, M.; Kelsen, D.
Article Title: A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma
Abstract: Purpose: This study investigated the feasibility of a novel approach to the treatment of malignant pleural mesothelioma by combining surgical resection with immediate postoperative intrapleural chemotherapy and subsequent systemic chemotherapy. Patients and Methods: Patients with biopsy- proven, resectable malignant pleural mesothelioma underwent pleurectomy/decortication immediately followed by intrapleural chemotherapy with cisplatin 100 mg/mg2 and mitomycin 8 mg/m2. Systemic chemotherapy was started 3 to 5 weeks postoperatively and included cisplatin 50 mg/m2 on days 1, 8, 15, 22, 36, 43, 50, and 57, and mitomycin 8 mg/m2 on days 1 and 36. Patients were then monitored by serial chest and abdominal computed tomographic (CT) scans every 3 months until death or for a minimum of 18 months, whichever occurred first. Results: Of 36 patients entered onto the study, 28 had pleurectomy/decortication and intrapleural chemotherapy. There was one postoperative death, and two episodes of grade 4 renal toxicity after intrapleural chemotherapy. The 23 patients who also had systemic chemotherapy received a median of 80% and 87% of the planned total cisplatin and mitomycin doses, respectively. No grade 3 or 4 toxicities were observed. The overall survival rate of the 27 patients who were originally candidates for systemic chemotherapy was 68% at 1 year and 40% at 2 years, with a median survival duration of 17 months. Locoregional disease was the most common form of relapse (16 of 20 patients). Conclusion: This short but aggressive combined modality regimen was generally well tolerated, but should not be used outside of a protocol setting because of the potential for serious toxicity. Overall survival was as good or better than with previously reported multimodality approaches, but other strategies are needed to improve local control.
Keywords: adult; cancer survival; clinical article; controlled study; aged; clinical trial; cancer recurrence; cisplatin; cancer staging; controlled clinical trial; nephrotoxicity; lung resection; pleura mesothelioma; mitomycin; pleurectomy; human; male; female; priority journal; article; intrapleural drug administration
Journal Title: Journal of Clinical Oncology
Volume: 12
Issue: 6
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1994-06-01
Start Page: 1156
End Page: 1163
Language: English
DOI: 10.1200/jco.1994.12.6.1156
PROVIDER: scopus
PUBMED: 8201377
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric Score
MSK Authors
  1. Venkatraman Ennapadam Seshan
    288 Seshan
  2. Valerie W Rusch
    657 Rusch
  3. Leonard B Saltz
    599 Saltz
  4. Robert J Ginsberg
    138 Ginsberg
  5. David P Kelsen
    341 Kelsen
  6. Michael E. Burt
    145 Burt